CC-90011

DRUG5 trials

Sponsors

Celgene

Conditions

Leukemia, MyeloidLymphoma, Non-HodgkinNeoplasmsProstatic NeoplasmsSmall Cell Lung Carcinoma

Phase 1

A Safety and Efficacy Study of CC-90011 in Participants With Relapsed and/or Refractory Solid Tumors and Non-Hodgkin's Lymphomas

TerminatedNCT02875223

CelgeneLymphoma, Non-Hodgkin, Neoplasms

Start: 2016-08-31End: 2024-03-25Updated: 2025-04-20

A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer

CompletedNCT03850067

CelgeneSmall Cell Lung Carcinoma

Start: 2019-03-12End: 2024-07-16Updated: 2024-08-26

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

CompletedNCT04628988

CelgeneProstatic Neoplasms

Start: 2021-07-28End: 2023-05-26Updated: 2023-09-13

A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy

TerminatedNCT04748848

CelgeneLeukemia, Myeloid

Start: 2021-10-14End: 2022-03-09Updated: 2023-03-02

Phase 2

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

CompletedNCT04350463

CelgeneNeoplasms

Start: 2020-07-14End: 2023-12-19Updated: 2025-01-22

Related Papers

Clinical activity of <scp>CC‐90011</scp>, an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies

Cancer2022-06-2345 citations

Phase 1/2 Study Investigating CC-90011, a Potent, Selective, and Reversible Oral Inhibitor of Lysine-Specific Demethylase 1 (LSD1), Plus Concurrent Venetoclax (VEN) and Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML)

Blood2021-11-054 citations

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Clinical Cancer Research2020-10-1241 citations

Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1)

Journal of Medicinal Chemistry2020-10-09114 citations

Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)

Annals of Oncology2019-02-0113 citations